Filana Therapeutics Inc.

FLNA | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.62

$0.00 (-0.32%)

Nov 2, 2026, 9:47 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

Key Executives

Name	Position
Richard Jon Barry	CEO, President & Director
Eric J. Schoen	Chief Financial Officer
Angelique Bordey	Senior Vice President of Neuroscience
George Thornton	Senior Vice President of Technology
Jack Moore	Senior Vice President of Clinical Development
Jaren Landen	Chief Clinical Development Officer
Joseph Hulihan	Chief Medical Officer
Michael Zamloot	Senior Vice President of Technical Operations
Nancy Teasdale	Head of Regulatory Affairs
R. Christopher Cook	Chief Operating & Legal Officer

Latest SEC Filings

Date	Type	Title
Apr 28, 2026	ARS	Filing
Apr 28, 2026	DEF 14A	Filing
Apr 28, 2026	8-K	Current Report
Mar 12, 2026	10-K	Annual Report
Mar 12, 2026	8-K	Current Report
Mar 10, 2026	8-K	Current Report
Feb 19, 2026	8-K	Current Report
Dec 23, 2025	8-K	Current Report
Dec 22, 2025	8-K/A	[Amend] Current Report
Dec 18, 2025	8-K	Current Report

View All SEC Filings ➞

Filana Therapeutics Inc.

Country	United States
IPO Date	Jul 14, 2000
Industry	Biotechnology
Sector	Healthcare
Employees	19
CEO	Richard Jon Barry

Contact Details

6801 N. Capital of Texas Highway Austin, Texas 78731 United States

https://www.filanatx.com

512 501 2444

Stock Details

Ticker Symbol	FLNA
Exchange	NASDAQ
Fiscal Year	n/a
Reporting Currency	USD
CIK Code	0001069530
CUSIP Number	14817C107
ISIN Number	US14817C1071
SIC Code	n/a